Stock Scorecard



Stock Summary for 10x Genomics Inc - Class A (TXG) - $9.65 as of 5/13/2025 9:12:48 PM EST

Total Score

12 out of 30

Safety Score

-2 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for TXG

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for TXG

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for TXG

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for TXG

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for TXG (-2 out of 100)

Stock Price Rating (Max of 10) 4
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 4
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) -40

Latest News for for TXG

Wall Street Analysts Believe 10x Genomics ( TXG ) Could Rally 55.85%: Here's is How to Trade 5/13/2025 1:55:00 PM
Cathie Wood Says AI Innovation In Healthcare Will Be More 'Profound' Than Autonomous Taxi Networks, Humanoid Robots - Amgen ( NASDAQ:AMGN ) , Bristol-Myers Squibb ( NYSE:BMY ) 5/12/2025 11:23:00 AM
10x Genomics CEO Calls NIH The 'Foundational Jewel' Of Biomedical Progress, Says 40% To 50% Of Revenue Supported By Academic And Government Research Funding - Pulls Full Year Revenue Guidance - 10x Genomics ( NASDAQ:TXG ) 5/9/2025 6:37:00 AM
10x Genomics ( TXG ) Reports Q1 Loss, Tops Revenue Estimates 5/8/2025 9:50:00 PM
Cathie Wood Pours $9.8 Million In Robinhood Despite Crypto Revenue Slump, Keeps Dumping Palantir Ahead Of Earnings - Advanced Micro Devices ( NASDAQ:AMD ) , ARK Innovation ETF ( BATS:ARKK ) 5/2/2025 1:35:00 AM
10x Genomics ( TXG ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release 5/1/2025 2:01:00 PM
Cathie Wood Sells Palantir Shares Worth $2.65 Million Ahead Of Earnings, Doubles Down On This Chip Giant - Advanced Micro Devices ( NASDAQ:AMD ) , ARK Innovation ETF ( BATS:ARKK ) 5/1/2025 2:36:00 AM
Tempus AI Stock Surges 43% in Q1: Buy Now or Wait for Earnings? 4/28/2025 7:00:00 PM
Cathie Wood Buys More NVIDIA And AMD Stock As Chinese Tech Giants Stockpile Chips Amid Looming US Export Curbs - Advanced Micro Devices ( NASDAQ:AMD ) , Adaptive Biotechnologies ( NASDAQ:ADPT ) 4/24/2025 1:23:00 AM
Cathie Wood's Thursday Plays: Healthcare AI And Crypto - Ark Scoops Up Tempus AI and Coinbase Stock Amid Trump Tariff Crash - Coinbase Global ( NASDAQ:COIN ) , ARK Innovation ETF ( BATS:ARKK ) 4/11/2025 2:12:00 AM

Financial Details for TXG

Company Overview

Ticker TXG
Company Name 10x Genomics Inc - Class A
Country USA
Description 10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and Asia Pacific. The company is headquartered in Pleasanton, California.
Sector Name LIFE SCIENCES
Industry Name LABORATORY ANALYTICAL INSTRUMENTS
Most Recent Quarter 3/31/2025
Next Earnings Date N/A

Stock Price History

Last Day Price 9.65
Price 4 Years Ago 148.96
Last Day Price Updated 5/13/2025 9:12:48 PM EST
Last Day Volume 4,138,378
Average Daily Volume 3,968,842
52-Week High 27.49
52-Week Low 6.78
Last Price to 52 Week Low 42.33%

Valuation Measures

Trailing PE N/A
Industry PE 37.56
Sector PE 49.22
5-Year Average PE -86.85
Free Cash Flow Ratio 2.80
Industry Free Cash Flow Ratio 124.79
Sector Free Cash Flow Ratio 31.82
Current Ratio Most Recent Quarter 5.37
Total Cash Per Share 3.45
Book Value Per Share Most Recent Quarter 5.74
Price to Book Ratio 1.65
Industry Price to Book Ratio 999.03
Sector Price to Book Ratio 30.58
Price to Sales Ratio Twelve Trailing Months 1.87
Industry Price to Sales Ratio Twelve Trailing Months 4.07
Sector Price to Sales Ratio Twelve Trailing Months 25.54
Analyst Buy Ratings 5
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 109,377,000
Market Capitalization 1,055,488,050
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 28.41%
Reported EPS 12 Trailing Months -1.30
Reported EPS Past Year -0.10
Reported EPS Prior Year -1.26
Net Income Twelve Trailing Months -157,036,000
Net Income Past Year -182,627,000
Net Income Prior Year -255,099,000
Quarterly Revenue Growth YOY 9.80%
5-Year Revenue Growth 19.96%
Operating Margin Twelve Trailing Months -31.30%

Balance Sheet

Total Cash Most Recent Quarter 377,061,000
Total Cash Past Year 344,067,000
Total Cash Prior Year 359,284,000
Net Cash Position Most Recent Quarter 377,061,000
Net Cash Position Past Year 344,067,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 19,837,000
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 710,134,000
Total Stockholder Equity Prior Year 741,043,000
Total Stockholder Equity Most Recent Quarter 706,895,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 44,364,000
Free Cash Flow Per Share Twelve Trailing Months 0.41
Free Cash Flow Past Year -5,729,000
Free Cash Flow Prior Year -64,721,000

Options

Put/Call Ratio 0.10
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.21
MACD Signal -0.33
20-Day Bollinger Lower Band 5.63
20-Day Bollinger Middle Band 11.44
20-Day Bollinger Upper Band 17.24
Beta 1.94
RSI 48.20
50-Day SMA 16.09
150-Day SMA 34.26
200-Day SMA 54.94

System

Modified 5/13/2025 12:48:59 PM EST